Evidence map›Paper›PMID 39949927›Full record

ArticleAmerican journal of cancer research2025

Tumor-treating fields and concurrent cisplatin: an

Austin R Smothers, Mya E Beasley, Hunter S Warren, Olivia G Kegel, W Jeffery Edenfield, John J O'Connell, Brian W Booth

Abstract read
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Austin R SmothersCenter for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University Clemson, SC, USA.
Mya E BeasleyCenter for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University Clemson, SC, USA.
Hunter S WarrenCenter for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University Clemson, SC, USA.
Olivia G KegelCenter for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University Clemson, SC, USA.
W Jeffery EdenfieldPrisma Health Cancer Institute, Prisma Health Greenville, SC, USA.
John J O'ConnellUniversity of South Carolina School of Medicine-Greenville Greenville, SC, USA.
Brian W BoothDepartment of Bioengineering, Clemson University Clemson, SC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy is commonly used to treat patients with triple-negative breast cancer. Combinations of platinum-based chemotherapies have demonstrated higher rates of pathologic complete responses of triple-negative breast cancer compared to combinations without platinum-based chemotherapies. However, there is a significant increase in general toxicity with the addition of platinum-based regimens. Some groups have investigated using tumor-treating fields as an alternative treatment method for triple-negative breast cancer, and chemosensitization by tumor-treating fields has been observed

Indexed as

Breast cancercisplatinconcurrent treatmenttriple-negativetumor treating fields

Identifiers

PMID39949927
PMCPMC11815381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.